Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study

Frontiers in Endocrinology

Endocrinology

Sara Volpe¹  Giuseppe Lisco¹  Margherita Fanelli¹  Carlo Sabb๠ Lucilla Crudele¹  Giuseppina Piazzolla¹  Valentina Colaianni¹  Davide Racaniello¹  Vincenzo Triggiani¹  Valentina Lavarra¹  Domenico Triggiani¹  Giovanni De Pergola² 

[1] Interdisciplinary Department of Medicine, School of Medicine, University of Bari “A. Moro”, Bari, Italy;Unit of Geriatrics and Internal Medicine, National Institute of Gastroenterology—IRCCS “Saverio de Bellis”, Bari, Italy;

关键词: oral semaglutide;    body composition;    fat mass;    visceral adipose tissue;    fat free mass;    skeletal muscle mass;    type 2 diabetes;    GLP-1RA;   

DOI  :  10.3389/fendo.2023.1240263

 received in 2023-06-14, accepted in 2023-08-28,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundOral semaglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1RA) designed for oral administration; it offers a promising opportunity to facilitate an early approach to Type 2 Diabetes (T2D). The study aimed to evaluate, in a real-life setting, the effects of oral semaglutide on the body composition of patients with T2D after 26 weeks of therapy.MethodsThirty-two patients with T2D were evaluated at baseline (T0) and after three (T3) and six (T6) months of therapy with oral semaglutide. At each time point, body composition was assessed using a phase sensitive bioimpedance analyzer. Clinical, anthropometric and laboratory parameters, and the main biometric surrogates of liver steatosis and fibrosis, were also analyzed and compared.ResultsA significant and early reduction in anthropometric and glucometabolic parameters, alanine aminotransferase, Fatty Liver Index, and Fat Mass was observed. Visceral Adipose Tissue (VAT) decreased, while Fat Free Mass and Skeletal Muscle Mass (SMM) were preserved during therapy, resulting in a beneficial increase in the SMM/VAT ratio. Finally, an overall improvement in body fluid distribution was observed.ConclusionOur real-world data confirm the clinical efficacy of oral semaglutide and highlight its ability to improve the nutritional status of patients with T2D.

【 授权许可】

Unknown   
Copyright © 2023 Volpe, Lisco, Fanelli, Racaniello, Colaianni, Lavarra, Triggiani, Crudele, Triggiani, Sabbà, De Pergola and Piazzolla